MTHFR epigenetic derepression protects against diabetes cardiac fibrosis

Area of Science:

• Cardiovascular Biology
• Epigenetics
• Metabolic Diseases

Background:

• Diabetes cardiac fibrosis involves altered DNA methylation of fibrogenic genes.
• The precise mechanisms driving these epigenetic changes and their impact on cardiac health remain largely unknown.

Purpose of the Study:

• Investigate the role of DNA methylation-driven suppression of MTHFR in diabetes cardiac fibrosis.
• Elucidate the protective mechanisms of folate in this context.
• Utilize diverse models including cell cultures, animal studies, and human samples.

Main Methods:

• Induced diabetes cardiac fibrosis in a mouse model using STZ.
• Assessed MTHFR expression and DNA methylation patterns in cardiac tissues from patients and mice.
• Manipulated DNMT3A levels to observe effects on MTHFR promoter methylation and cardiac fibrosis.
• Administered folate supplementation to evaluate its therapeutic potential.

Main Results:

• MTHFR expression was significantly reduced in cardiac fibrosis associated with diabetes.
• Increased levels of DNMT3A and MTHFR promoter methylation correlated with fibrosis.
• DNMT3A knockdown reversed MTHFR suppression, alleviated fibrosis, and reduced cardiac fibroblast pyroptosis.
• Folate supplementation effectively rescued MTHFR loss and mitigated cardiac fibrosis.

Conclusions:

• Aberrant DNMT3A elevation and MTHFR promoter hypermethylation are key epigenetic features of diabetes cardiac fibrosis.
• MTHFR repression is a critical mediator of cardiac fibrosis in diabetes.
• Folate supplementation demonstrates protective effects against diabetes cardiac fibrosis by targeting these epigenetic alterations.